"Pharmacogenomic Variants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Naturally occurring genetic variations associated with drug response (e.g., dosage, extent and rate of metabolic processes). While these variants are not markers for GENETIC PREDISPOSITION TO DISEASE they influence PHARMACOKINETICS and pharmacodynamics and often occur on genes encoding drug metabolism enzymes and transporters (e.g., ANGIOTENSIN CONVERTING ENZYME; CYTOCHROME P-450 CYP2D6).
| Descriptor ID |
D000071184
|
| MeSH Number(s) |
G05.365.795.446
|
| Concept/Terms |
Pharmacogenomic Variants- Pharmacogenomic Variants
- Pharmacogenomic Variant
- Variant, Pharmacogenomic
- Variants, Pharmacogenomic
- Pharmacokinetic Genetic Variants
- Genetic Variant, Pharmacokinetic
- Genetic Variants, Pharmacokinetic
- Pharmacokinetic Genetic Variant
- Pharmacogenetic Variants
- Pharmacogenetic Variant
- Variant, Pharmacogenetic
- Variants, Pharmacogenetic
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenomic Variants".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenomic Variants".
This graph shows the total number of publications written about "Pharmacogenomic Variants" by people in this website by year, and whether "Pharmacogenomic Variants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 2 | 1 | 3 |
| 2017 | 3 | 1 | 4 |
| 2018 | 5 | 0 | 5 |
| 2019 | 1 | 4 | 5 |
| 2020 | 1 | 1 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacogenomic Variants" by people in Profiles.
-
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
-
Should secondary pharmacogenomic variants be actively screened and reported when diagnostic genome-wide sequencing is performed in a child? Genet Med. 2024 02; 26(2):101033.
-
Defining the risk of SARS-CoV-2 variants on immune protection. Nature. 2022 05; 605(7911):640-652.
-
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer. Clin Pharmacol Ther. 2021 10; 110(4):1038-1049.
-
Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age at Disease Onset. JAMA Netw Open. 2020 12 01; 3(12):e2028644.
-
Genetic Variant in CHRNA5 and Response to Varenicline and Combination Nicotine Replacement in a Randomized Placebo-Controlled Trial. Clin Pharmacol Ther. 2020 12; 108(6):1315-1325.
-
Interplay Between Statins, Cav1 (Caveolin-1), and Aldosterone. Hypertension. 2020 09; 76(3):962-967.
-
Pragmatic Trials in Genomic Medicine: The Integrating Pharmacogenetics In Clinical Care (I-PICC) Study. Clin Transl Sci. 2020 03; 13(2):381-390.
-
Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response. Sci Rep. 2019 11 21; 9(1):17323.
-
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers. PLoS One. 2019; 14(9):e0221957.